Type Public company
------------ --------------------------------------
Industry Pharmaceutical industry
Founded 1981
Founder Alexander Rich Paul Schimmel
Headquarters Waltham, Massachusetts , United States
What does Repligen make?
biological drugs
How many employees does Repligen have?
Repligen Annual Number of Employees
-----------------------------------
2020
2019
2018
2017
Is Repligen a buy?
Repligen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
What kind of company is Repligen?
bioprocessing
Will Repligen stock go up?
Will Repligen stock price grow / rise / go up? Yes. The RGEN stock price can go up from 202.370 USD to 271.032 USD in one year.
Why is RGEN falling?
RGEN stock reached its all-time high of around $327 just after the announcement, but profit-booking at higher levels resulted in RGEN stock falling to levels of $259 currently.12 Oct 2021
Who is Repligen owned by?
Type Public company
------------ --------------------------------------
Founded 1981
Founder Alexander Rich Paul Schimmel
Headquarters Waltham, Massachusetts , United States
Key people Tony J. Hunt (President) and CEO)
What does Repligen company do?
Repligen is a bioprocessing-focused life sciences company bringing expertise and innovation to our customers since 1981. We are inspiring advances in bioprocessing through the development and commercialization of high-value products and flexible solutions that address critical steps in the production of biologic drugs.
What does Repligen sell?
Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN.